Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization, and causes bladder cancer in cooperation with p53 dysfunction.

CONCLUSIONS: Our findings provide insights into multistep carcinogenic processes of BC and suggest molecular targeted therapeutic approaches for BC patients with Kdm6a dysfunction.
PMID: 32047002 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 10, 2020 Category: Cancer & Oncology Authors: Kobatake K, Ikeda K, Nakata Y, Yamasaki N, Ueda T, Kanai A, Sentani K, Sera Y, Hayashi T, Koizumi M, Miyakawa Y, Inaba T, Sotomaru Y, Kaminuma O, Ichinohe T, Honda ZI, Yasui W, Horie S, Black PC, Matsubara A, Honda H Tags: Clin Cancer Res Source Type: research